Straits Times Index
3,381.05 +17.37 (+0.52%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,630.00 -328.36 (-1.50%) FTSE 100
7,820.16 0.00 (0.00%) BTC-USD
23,472.83 -319.70 (-1.34%) CMC Crypto 200
535.15 -10.16 (-1.86%)
Novartis AG (NVSEF)
| Previous close | 87.57 |
| Open | 86.07 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 86.07 - 86.07 |
| 52-week range | 72.98 - 93.58 |
| Volume | |
| Avg. volume | 45,236 |
| Market cap | 182.445B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 27.15 |
| EPS (TTM) | 3.17 |
| Earnings date | N/A |
| Forward dividend & yield | 3.35 (3.82%) |
| Ex-dividend date | 08 Mar 2022 |
| 1y target est | N/A |
- Zacks
Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
- Motley Fool
Novartis Ag (NVS) Q4 2022 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2022.
- Reuters
Novartis says operating profit to grow again ahead of Sandoz spin-off
Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4% to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya.
